Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

Video

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

There are three structural parts to a CAR T cell: the ligand which binds to the target on the surface of the B-cell lymphoma, the transmembrane domain, and stimulatory molecules, says Sehgal. Two aspects go into the stimulatory molecules, including CD3 zeta, which is part of the T-cell receptor as well as a costimulatory domain, which can vary between the CD28 and 4-1BB products, she adds.

Regarding the manufacturing process, eligible patients will undergo 1 day of leukapheresis so that their T cells can be collected. Patients do not have to undergo mobilization ahead of time, which differs from the protocol for stem cell transplant. After the T cells have been collected, they are sent to the manufacturing center for a time period of approximately 2 to 4 weeks, explains Sehgal. Once the T cells have been grown sufficiently, the patient comes in to the hospital and receives 3 days of chemotherapy prior to receiving their transfusion anywhere from 2 to 7 days later.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.